Ciencia Básica

Dr. José Luis Pablos Álvarez
Hospital Universitario 12 de Octubre
Madrid
Resumen Sesiones Ciencia Básica

Abstracts: Innate Immunity 4:00 PM - 4:10 PM CET
- Neutrophils Mediate Kidney Inflammation Following Acute Skin Exposure to UV Light
- ENPP1 Regulates UV Light Triggered Type I Interferon Response in the Skin

Plenary Session II 11:45 AM – 12:00 PM ET:
- Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Trial of BIIB059, an Anti-Blood Dendritic Cell Antigen 2 Antibody, in SLE
  [Monday, November 9, 2020 12:30 PM – 12:45 PM ET: Targeting Plasmacytoid Dendritic Cells Improves Cutaneous Lupus Erythematosus Skin Lesions and Reduces Type I Interferon Levels: Results of a Phase 1 Study of VIB7734]
- Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis

Abstracts: Muscle Biology, Myositis & Myopathies 4:20 PM - 4:30 PM CET
- Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis

Abstracts Rheumatoid arthritis (RA) 11:00 PM – 11:50 PM CET
- Abstracts: RA – Etiology & Pathogenesis
- Abstracts: RA – Animal Models
Acute Skin Exposure To UV Light Triggers Neutrophil-mediated Kidney Inflammation
Sladjana Skopelja-Gardner, Joyce Tai, Xizhang Sun, Lena Tanaka, James Kuchenbecher, Paul Kubes, and Keith Elkon
ENPP1 Regulates UV Light Triggered Type I Interferon Response in The Skin
Sladjana Skopelja-Gardner, Joyce Tai, Xizhang Sun, Lena Tanaka, and Keith Elkon
BIIB059 administration in (12) patients with SLE decreased expression of IFN response genes in blood, normalized MxA expression, reduced immune infiltrates in skin lesions, and decreased CLASI-A score.
Efficacy and Safety Results from a Phase 2, Randomized, Double-blind Trial of BIIB059, an Anti-Blood Dendritic Cell Antigen 2 Antibody, in Systemic Lupus Erythematosus

Furie RA,1 van Vollenhoven RF,2 Kalunian K,3 Navarra S,4 Romero-Diaz J,5 Werth VP,6 Huang X,7 Carroll H,7 Meyers A,7 Musselli C,7 Barbey C,8 Franchimont N7

1Northwell Health, Great Neck, NY, USA; 2Amsterdam University Medical Centers, Amsterdam, Netherlands; 3University of California San Diego, La Jolla, CA, USA; 4University of Santo Tomas, Manila, Philippines; 5Instituto Nacional de Ciencias Medicas y Nutricion SZ, Mexico City, Mexico; 6University of Pennsylvania and Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA; 7Biogen, Cambridge, MA, USA; 8Biogen, Baar, Switzerland
Conclusion

• The **primary endpoint was met**
  • Doses of BIIB059 450 mg se every 4 weeks for 20 weeks significantly reduced the total active joint count at Week 24
  • At Week 24, a significantly **higher** percentage of participants who received B118059 compared to placebo achieved an **SRI-4 response**
  • At Week 24, a **higher** percentage of participants who received B11B059 compared to placebo achieved a **CLASI-50 response**
  • The majority of AEs were **mild** or **moderate** Zoster? 2/56 PBO and 2/64 B11B059
  • The incidence of SAEs was **similar** in the BIIB059 and placebo groups
Viela Bio VIB7734 target and bind to ILT7, a cell surface molecule specific to pDCs.

Conclusion: VIB7734 reduced blood and skin pDCs, thereby reducing type I IFN levels in blood and inflamed skin. More CLE subjects treated with VIB7734 than placebo had a clinically significant improvement in CLASI-A scores, and VIB7734 had an acceptable safety profile. Additional studies of VIB7734 in lupus are planned.
Mitochondrial ROS as a Regulator of Calcinosis in Juvenile Dermatomyositis

Bhargavi Duvvuri\textsuperscript{1}, Lauren M. Pachman\textsuperscript{2,3,}
Richard Moore\textsuperscript{1}, Stephen Doty\textsuperscript{4} and Christian Lood\textsuperscript{1}

\textsuperscript{1}Division of Rheumatology, University of Washington, Seattle, WA, USA
\textsuperscript{2}Division of Pediatric Rheumatology, Department of Pediatrics, The Ann and Robert H. Lurie Children’s Hospital, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
\textsuperscript{3}CureJM Center of Excellence, The Ann and Robert H. Lurie Children’s Hospital and the Stanley Manne Children’s Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
\textsuperscript{4}The Hospital for Special Surgery, New York, New York, USA
JDM fibras con mitocondrias calcificadas

Mitocondrias calcificadas extracelulares

DNA mitocondrial plasma con calcinosis

Modelo fibras in vitro depende ROS IFNA STAT3

0971. Single-cell Profiling of Synovial Stromal Cells Reveals an Angiocrine Endothelium in Rheumatoid Arthritis
Kevin Wei, Kevin Wei
Brigham and Women's Hospital
9:10 PM - 9:20 PM CET (Sat, Nov 7)

0965. Repetitive Inhalant Lipopolysaccharide Exposure in the Setting of Arthritis Induction Potentiates Pro-Fibrotic Inflammatory Lung Disease in Mice
Madison Wolfe, BS
University of Nebraska Medical Center
11:00 PM - 11:10 PM CET (Sat, Nov 7)

0973. Novel Network Tool Highlights Key Features Associated with Disease Pathotypes and Response to Treatment in Early Rheumatoid Arthritis
Elisabetta Sciacca, PhD
Experimental Medicine & Rheumatology (EMR)
9:30 PM - 9:40 PM CET (Sat, Nov 7)

0970. Oxylipins Profiles During the Earliest Phases of Rheumatoid Arthritis: Associations with Clinical Stage and Treatment Outcomes
Roxana Coras, MD
University of California San Diego/Department of Medicine, Autonomous University of Barcelona
9:00 PM - 9:10 PM CET (Sat, Nov 7)
Urine Proteomics and Single Cell Transcriptomics Identify IL-16 as a Biomarker for Lupus Nephritis

Andrea Fava, Jill Buyon, Chandra Mohan, Ting Zhang, H. Michael Belmont, Peter Izmirly, Robert Clancy, Jose Monroy Trujillo, Derek Fine, Arnon Arazzi, Celine C. Berthier, Anne Davidson, Betty Diamond, Nir Hacohen, David Wofsy, William Apruzzese, Deepak A. Rao, Soumya Raychaudhuri, the Accelerating Medicines Partnership in RA/SLE network, and Michelle Petri